Skip to content
Screener

Hinge Health HNGE Business Segments — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Bicara Therapeutics logo
BCAXReportable Segment — R&D
$47.5M+38.4%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%

Other financials

Income statement

See full
Revenue$212.8M+53.0%
Gross profit$183.9M+88.2%
Operating income$40.4M+107%
Net income$43.7M+108%
EPS (diluted)$0.52+104%

Balance sheet

See full
Cash & equivalents$287.7M+20.4%
Total debt$5.9M-40.9%
Total equity$344.3M+98.1%
Total assets$827.4M+19.3%

Cash flow

See full
Operating cash flow$101.4M+401%
CapEx$123.0K-37.6%
Free cash flow$101.3M+406%

Valuation

See full
Market cap$6.2B+31.2%
Enterprise value$5.91B+31.6%
P/E80.5×
P/S8.6×-1.2×

Profitability

See full
Gross margin84.5%+6.8pp
Operating margin9.2%
Net margin10.7%
FCF margin40.3%+21.3pp

Returns & leverage

See full
Return on equity29.7%
Debt / equity0.0×
Current ratio1.3×-0.6×

Where this comes from

Reported directly by Hinge Health in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Hinge Health’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:14 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-054327
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Acquisition and other expenses (1)4401,3371,1342,968
Stock-based compensation expense (2)19,092590,98330,784590,990
Other segment income (loss) (3)(1,710)9,430(3,060)5,610
Cost of revenue (excluding 1,2,3)27,47123,77754,37847,188
Research and development (excluding 1,2,3)25,90822,77451,44744,816
Sales and marketing (excluding 1,2,3)75,07149,549139,46096,264
General and administrative (excluding 1,2,3)22,85516,89942,16333,599
Net income (loss)$43,690$(575,651)$78,818$(558,512)

Item 1. Financial Statements (Unaudited)

FAQ

What is Hinge Health's business segments — R&D?
Hinge Health (HNGE) reported business segments — R&D of $25.91M in Q2 2026.
How has Hinge Health's business segments — R&D changed year-over-year?
Hinge Health's business segments — R&D increased by 13.8% year-over-year, from $22.77M to $25.91M.
What does business segments — R&D mean?
Measures the investment in developing, maintaining, and improving the company's AI-powered motion tracking technology and clinical platform features. This spending is a primary driver of future innovation and competitive differentiation in the musculoskeletal health market. Investors monitor this to gauge the company's commitment to technological leadership and product evolution.

Ask your AI about Hinge Health's business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude